RU97104483A - SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT - Google Patents

SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT

Info

Publication number
RU97104483A
RU97104483A RU97104483/04A RU97104483A RU97104483A RU 97104483 A RU97104483 A RU 97104483A RU 97104483/04 A RU97104483/04 A RU 97104483/04A RU 97104483 A RU97104483 A RU 97104483A RU 97104483 A RU97104483 A RU 97104483A
Authority
RU
Russia
Prior art keywords
compound according
purin
cyclopropylamino
methanol
amino
Prior art date
Application number
RU97104483/04A
Other languages
Russian (ru)
Other versions
RU2145324C1 (en
Inventor
Сьюзен Мери Дейлюдж
Джеффри Даглас Уилсон
Original Assignee
Де Вэллкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417249A external-priority patent/GB9417249D0/en
Application filed by Де Вэллкам Фаундейшн Лимитед filed Critical Де Вэллкам Фаундейшн Лимитед
Publication of RU97104483A publication Critical patent/RU97104483A/en
Application granted granted Critical
Publication of RU2145324C1 publication Critical patent/RU2145324C1/en

Links

Claims (10)

1. Соль янтарной кислоты (1S, 4R)-цис-4-[2-амино-6-(циклопропиламино)-9H-пурин-9-ил]-2- циклопентен-1-метанола.1. The salt of succinic acid (1S, 4R) -cis-4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopentene-1-methanol. 2. Сольват соединения по п. 1. 2. The solvate of the compound according to claim 1. 3. Гидрат соединения по п. 1. 3. The hydrate of the compound according to claim 1. 4. Способ лечения или профилактики вирусных инфекций у человека, который включает введение указанному хозяину эффективного количества соединения по п. 1. 4. A method of treating or preventing viral infections in humans, which comprises administering to the indicated host an effective amount of a compound according to claim 1. 5. Соединение по пп. 1-3, отличающееся тем, что его используют в медицинской терапии. 5. Connection PP. 1-3, characterized in that it is used in medical therapy. 6. Применение соединения по пп. 1-3 в производстве лекарства для лечения или профилактики вирусной инфекции. 6. The use of compounds according to paragraphs. 1-3 in the manufacture of a medicament for the treatment or prevention of a viral infection. 7. Способ получения соединения по п. 1, при котором смешивают (1S, 4R)-цис-4-[2-амино-6-(циклопропиламино)-9H-пурин-9-ил] -2-циклопентен- 1-метанола в подходящем растворителе с янтарной кислотой в воде и в таких условиях, чтобы осуществить образование соединения по п. 1. 7. A method of producing a compound according to claim 1, wherein (1S, 4R) -cis-4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopentene-1-methanol is mixed in a suitable solvent with succinic acid in water and under such conditions to effect the formation of a compound according to claim 1. 8. Фармацевтический состав, включающий соединение по пп. 1-3 и по меньшей мере один фармацевтически приемлемый его носитель. 8. The pharmaceutical composition comprising a compound according to claims. 1-3 and at least one pharmaceutically acceptable carrier thereof. 9. Фармацевтический состав по п. 8, отличающийся тем, что он сформован в таблетку или капсулу. 9. The pharmaceutical composition according to claim 8, characterized in that it is molded into a tablet or capsule. 10. Фармацевтический состав по п. 8, отличающийся тем, что он приспособлен для парэнтерального введения. 10. The pharmaceutical composition according to p. 8, characterized in that it is adapted for parenteral administration.
RU97104483A 1994-08-26 1995-08-25 4-[2-amino-6-(cyclopropylamino)-9h-purine-9-yl]-2-cyclopentene- -1-methanol succinate as antiviral agent RU2145324C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9417249A GB9417249D0 (en) 1994-08-26 1994-08-26 A novel salt
GB9417249.1 1994-08-26
PCT/GB1995/002014 WO1996006844A1 (en) 1994-08-26 1995-08-25 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent

Publications (2)

Publication Number Publication Date
RU97104483A true RU97104483A (en) 1999-05-20
RU2145324C1 RU2145324C1 (en) 2000-02-10

Family

ID=10760434

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97104483A RU2145324C1 (en) 1994-08-26 1995-08-25 4-[2-amino-6-(cyclopropylamino)-9h-purine-9-yl]-2-cyclopentene- -1-methanol succinate as antiviral agent

Country Status (23)

Country Link
EP (1) EP0777669B1 (en)
JP (1) JPH10505593A (en)
KR (1) KR100376240B1 (en)
CN (1) CN1051550C (en)
AT (1) ATE220067T1 (en)
AU (1) AU702618B2 (en)
BR (1) BR9508629A (en)
CA (1) CA2198010C (en)
DE (1) DE69527294T2 (en)
DK (1) DK0777669T3 (en)
ES (1) ES2179110T3 (en)
FI (1) FI120403B (en)
GB (1) GB9417249D0 (en)
HU (1) HU221302B1 (en)
IL (1) IL115074A (en)
MX (1) MX9701273A (en)
NO (1) NO315200B1 (en)
NZ (1) NZ291862A (en)
PT (1) PT777669E (en)
RU (1) RU2145324C1 (en)
SI (1) SI0777669T1 (en)
WO (1) WO1996006844A1 (en)
ZA (1) ZA957166B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU7912398A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
SK284595B6 (en) * 1997-11-27 2005-07-01 Lonza Ag Method for the production of (1S,4R)-4-(2-amino-6-chloro-9H- purine-9-yl)-2-cyclopentene-1-methanol or its salts
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9903091D0 (en) * 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
AU2002355739A1 (en) 2001-07-30 2003-02-17 University Of Southern California Preparation and use of alpha-keto phosphonates
JP4542550B2 (en) * 2003-10-27 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション CCR-2 antagonist salt
EP2305680A3 (en) * 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
EP2697238B1 (en) 2011-04-08 2019-03-20 Laurus Labs Limited Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3025492A1 (en) * 1980-07-04 1982-02-04 Siemens AG, 1000 Berlin und 8000 München FILTER ELEMENT FOR OPTICAL MESSAGE TECHNOLOGY
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate

Similar Documents

Publication Publication Date Title
RU2203653C2 (en) Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof
CN1043610C (en) Novel treatment
RU95107881A (en) Pharmaceutical composition for allergic disease treatment, method of antihistamine treatment, use of composition for medicinal preparation preparing
LV12399A (en) Enhanced once-a-day pulse minicyclic mini-cycling systems
RU93057724A (en) PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARATION AND METHOD OF TREATMENT
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
DK165733B (en) USE OF DIPEPTIDE DERIVATIVES FOR THE PREPARATION OR TREATMENT OF POSTTRAUMATIC NERVOUS DAMAGE AFTER ACCIDENTALLY REVERSED SPINE AND / OR Brain traumas.
RU95101385A (en) Products containing g-csf and tnf-binding protein
ATE99172T1 (en) USE OF ACETYL-L-CARNITINE IN TREATMENT OF CATARACT, AND PHARMACEUTICAL COMPOSITIONS FOR SUCH TREATMENT.
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
KR970705563A (en) (2-amino-6- (cyclopropylamino) -9H-purin-9-yl) -2-cyclopentene-1-methanol succinate -9H-Purin-9-yl) -2-cyclopentene-1-methanol Succinate as Antiviral Agent)
RU99119233A (en) PHARMACEUTICAL COMPOSITIONS containing ibuprofen and domperidone for the treatment of migraine
EP0514023B1 (en) Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
JPH03109324A (en) Vascularization inhibitor
US5510390A (en) Anti-hypertensive composition and methods of treatment
KR900701278A (en) Bile acids for the treatment of viral infections
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
CA1209047A (en) Therapeutic composition containing piracetam analog
JP5386476B2 (en) Use of 4-cyclopropylmethoxy-N- (3,5-dichloro-1-oxide-4-pyridin-4-yl) -5- (methoxy) pyridine-2-carboxamide for the treatment of cranial trauma
KR950700063A (en) Brofaromine as an agent for treating post-traumatic stress
JPH0193526A (en) Recovering agent for reduction in leukocyte
CN1084622C (en) Pharmaceuticals
WO1998057626A1 (en) Use of l-arginine or a pharmaceutically acceptable salt thereof for production of drugs for treatment of helicobacter pylori infections
RU2071780C1 (en) Method of treatment of medicinal esophago-gingivo-stomatitis
US3689643A (en) Combination of l-dopa, 2-imino-5-phenyl-4-oxazolidinone and an aluminum or alkaline earth metal salt or base used to treat parkinson{40 s disease